Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Study Evaluating the Efficacy of DOSE Formulations in Treatment of Melasma and Cutaneous Signs of Aging

NCT04137263 is registered in ClinicalTrials.gov with Goldman, Butterwick, Fitzpatrick and Groff as lead sponsor.

NCT NCT04137263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04137263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Study Evaluating the Efficacy of DOSE Formulations in Treatment of Melasma and Cutaneous Signs of Aging
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Phase
Not applicable
Overall status
Completed
Start date
October 1, 2019
Completion date
December 1, 2020
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melasma